Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 60.20K | 106.20K | 34.90K | 53.70K | 3.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.40K | 124.70K | 48.80K | 100.30K | 3.97M |
| Operating Income | -71.40K | -124.70K | -48.80K | -100.30K | -3.97M |
| Income Before Tax | -95.50K | -147.60K | -58.30K | -105.20K | -4.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.50K | -147.60K | -58.30K | -105.20K | -4.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.50K | -147.60K | -58.30K | -105.20K | -4.13M |
| EBIT | -71.40K | -124.70K | -48.80K | -100.30K | -3.97M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 771.81M | 771.81M | 770.27M | 771.81M | 588.52M |
| Average Diluted Shares Outstanding | 771.81M | 771.81M | 770.27M | 771.81M | 588.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
